From the Journals

AI, multiomics help advance endocrine HTN

“This review matters because endocrine hypertension remains one of the few potentially curable forms of hypertension."

Share

The integration of multiomics profiling and artificial intelligence (AI) is revolutionizing the diagnosis and subtyping of endocrine hypertension (EH), which affects 5-10% of hypertension cases. Primary aldosteronism (PA) is particularly underdiagnosed, with screening rates below 1%. Leveraging AI and multiomics could significantly boost diagnostic accuracy and promote personalized treatment, ultimately aiming for earlier detection and improved patient outcomes. This narrative review provides insights into innovations and challenges in implementing these technologies in routine clinical practice.

Original Source(s)

AI, multiomics help advance endocrine HTN

  • by Doug Brunk

  • March 18, 2026

Related Content

Expanding CGM Access for Medicare Patients

“Insurance coverage of CGM is frequently identified in the literature as a barrier to CGM access."

Evaluating AI for thyroid nodule diagnosis

Ultrasound based AI–assisted diagnostic systems “demonstrated high clinical potential."

AI models may improve PCOS detection

Researchers cite accuracy gains alongside concerns about limited validation and model transparency.